Genedrive PLC - Manchester, England-based molecular diagnostics company - Says initial orders of its MT-RNR1 products from France, Austria, the Netherlands, Greece, Saudi Arabia and Turkey have been received. News follows confirmation that commercial distribution agreements were signed in multiple countries for Genedrive’s test for antibiotic induced hearing loss. Genedrive says these initial orders will support its international distribution partners in promotion and in-country evaluation activities in their respective countries. Hopes this will ‘provide more extensive access to this life-changing test.’

Chief Executive Officer James Cheek says: ‘We are delighted to see the first orders come in from those countries we have signed distribution agreements with.

‘We look forward to the continued expansion of our international sales throughout 2024 as we drive forward with our sales and marketing strategies and deliver value to our shareholders.’

Current stock price: 9.65 pence, up 21% on Wednesday morning in London

12-month change: down 1.0%

Copyright 2023 Alliance News Ltd. All Rights Reserved.